Qilu Pharmaceutical Secures IND Approval in China for CEND-1 in First-Line Treatment of Metastatic Pancreatic Cancer

According to the public disclosure from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), CEND-1 for injection, licensed in by Qilu Pharmaceutical, has received tacit approval for a clinical trial. It is intended for development as a first-line treatment for advanced metastatic pancreatic cancer. Publicly available information indicates that CEND-1 is a potential "first-in-class" anticancer therapy developed by Cend Therapeutics, and Qilu Pharmaceutical holds exclusive rights to this candidate drug in the Greater China region (including mainland China, Hong Kong, Macao, and Taiwan).

Screenshot source: CDE official website

According to the CDE's public disclosure, the clinical trial indication approved for CEND-1 in China is: CEND-1 in combination with gemcitabine and paclitaxel for injection (albumin-bound) for the first-line treatment of advanced metastatic pancreatic cancer.